Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02231710 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
A Phase 1 study, sponsored by Bellicum Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02231710 is a Phase 1 study that was terminated before completion, run by Bellicum Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT02231710, a Phase 1 study, was terminated before completion, sponsored by Bellicum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of Rimiducid (AP1903) on day 7 to prevent GVHD.
Interventions
- BIOLOGICAL BPX-501 and Rimiducid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-02 |
| Est. Completion | 2018-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02231710
The ClinicalTrials.gov registry entry for NCT02231710 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bellicum Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BPX-501 and Rimiducid is the first listed.
NCT02231710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02231710 about?
NCT02231710 is a clinical study titled "Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases". The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of Rimiducid (AP1903) on day 7 to prevent GVHD.
What is the current status of trial NCT02231710?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2015-02. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02231710?
The interventions under investigation include: BPX-501 and Rimiducid (BIOLOGICAL).
Who is sponsoring clinical trial NCT02231710?
This trial is sponsored by Bellicum Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.